ოთხშაბათი, აპრილი 15, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Nootropics

Maizinol

Crocus sativus

Also known as: Saffron extract, Affron, Safranal, Crocin extract

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Maizinol is a branded saffron-derived extract used for mood, sleep, and eye health. Saffron extracts are generally safe at standardised low doses (28–30 mg/day). At high doses, saffron can cause uterine contractions, vomiting, and mucosal bleeding. It may have mild serotonergic activity and should be used cautiously with SSRIs and other serotonergic medications. Avoid in pregnancy.

Classification

Biological and Chemical Classification

Scientific Name
Crocus sativus
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Nootropics
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Nootropics
Ingredient Maizinol
Scientific name Crocus sativus
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Nootropics
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Maizinol indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Maizinol
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Crocus sativus
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 14:07

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Csa-miR160 targets transcriptional repressor CsARF18 and modulates auxin-mediated crocin biosynthesis in Crocus sativus L. ↗
    PMID 41838799 ↗
    Journal Plant Physiol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41838799/
    Xing B et al.. Csa-miR160 targets transcriptional repressor CsARF18 and modulates auxin-mediated crocin biosynthesis in Crocus sativus L.. Plant Physiol. 2026. PMID:41838799.
  2. Observational / other LOW evidence YELLOW
    From Plains to Mountains: Results of Current and Future Climatic Suitability Analysis for Crocus sativus L. Cultivation in Italy. ↗
    PMID 41829725 ↗
    Journal Plants (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41829725/
    Giupponi L et al.. From Plains to Mountains: Results of Current and Future Climatic Suitability Analysis for Crocus sativus L. Cultivation in Italy.. Plants (Basel). 2026. PMID:41829725.
  3. Observational / other LOW evidence YELLOW
    Organic priming strategies enhance antioxidant defense and suppress corm rot in saffron: role of Trichoderma and walnut leaf powder. ↗
    PMID 41811465 ↗
    Journal Protoplasma
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41811465/
    Bashir T et al.. Organic priming strategies enhance antioxidant defense and suppress corm rot in saffron: role of Trichoderma and walnut leaf powder.. Protoplasma. 2026. PMID:41811465.
  4. Observational / other LOW evidence YELLOW
    Design and optimisation of rapid quadruplex PCR technique to identify plant-derived adulterants in saffron. ↗
    PMID 41788453 ↗
    Journal J Food Sci Technol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41788453/
    Boudadi I et al.. Design and optimisation of rapid quadruplex PCR technique to identify plant-derived adulterants in saffron.. J Food Sci Technol. 2026. PMID:41788453.
  5. Observational / other LOW evidence YELLOW
    Crocin Mitigates Glutamate Excitotoxicity and Tau Hyperphosphorylation by Modulating EAAT2 and Akt/Tau Pathway in a Scopolamine-induced Rat Model of Alzheimer's Disease. ↗
    PMID 41784832 ↗
    Journal Neurochem Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41784832/
    El-Baga SE et al.. Crocin Mitigates Glutamate Excitotoxicity and Tau Hyperphosphorylation by Modulating EAAT2 and Akt/Tau Pathway in a Scopolamine-induced Rat Model of Alzheimer's Disease.. Neurochem Res. 2026. PMID:41784832.
  6. Observational / other LOW evidence YELLOW
    Promising synergistic interactions and mixture optimization of safranal, crocin, and crocetin from Moroccan Crocus sativus L. with enhanced antimicrobial activity. ↗
    PMID 41769694 ↗
    Journal Front Pharmacol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41769694/
    Baraich A et al.. Promising synergistic interactions and mixture optimization of safranal, crocin, and crocetin from Moroccan Crocus sativus L. with enhanced antimicrobial activity.. Front Pharmacol. 2026. PMID:41769694.
  7. Observational / other LOW evidence YELLOW
    Exploring the neurofunctional potential of saffron bioactives: from mood-related behavioral modulation to brain access of safranal. ↗
    PMID 41758529 ↗
    Journal Food Funct
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41758529/
    Monchaux de Oliveira C et al.. Exploring the neurofunctional potential of saffron bioactives: from mood-related behavioral modulation to brain access of safranal.. Food Funct. 2026. PMID:41758529.
  8. Observational / other LOW evidence YELLOW
    Crocin protects against smoke-induced chronic obstructive pulmonary disease by regulating AKT1. ↗
    PMID 41737560 ↗
    Journal Front Pharmacol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41737560/
    Zhu Y et al.. Crocin protects against smoke-induced chronic obstructive pulmonary disease by regulating AKT1.. Front Pharmacol. 2026. PMID:41737560.
  9. Observational / other LOW evidence YELLOW
    Field-deployable LAMP assay for rapid and specific detection of Fusarium oxysporum causing corm rot in saffron. ↗
    PMID 41724110 ↗
    Journal Talanta
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41724110/
    Tripathi V et al.. Field-deployable LAMP assay for rapid and specific detection of Fusarium oxysporum causing corm rot in saffron.. Talanta. 2026. PMID:41724110.
  10. Observational / other LOW evidence YELLOW
    Medicinal plants in the management of muscle loss and sarcopenia: A narrative review of preclinical and clinical evidence from eight species. ↗
    PMID 41720015 ↗
    Journal Phytomedicine
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41720015/
    Yazdanpanah Z et al.. Medicinal plants in the management of muscle loss and sarcopenia: A narrative review of preclinical and clinical evidence from eight species.. Phytomedicine. 2026. PMID:41720015.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for Maizinol. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Maizinol

GIRI Score 2.0 / 10

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge